ANTI-PD-1 HUMANIZED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION THEREOF

The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of PD...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	FU, Jun, HUO, Yongting, LU, Lisheng, LI, Fan, ZHANG, Zhe, LU, Di, GONG, Chunxi
Format:	Patent
Sprache:	chi ; eng ; fre
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present application relates to the field of biomedical technology, and specifically, provides an anti-PD-1 humanized antibody or an antigen-binding fragment thereof and an application thereof. The antibody can efficiently and specifically bind to PD-1, and can effectively block the binding of PD-1 to PD-L1 and PD-L2. Therefore, the antibody or antigen-binding fragment thereof, and its related nucleic acid, vector, cell, or pharmaceutical composition can be used to prepare a medicament for the treatment of PD-1 mediated diseases or conditions. La présente demande relève du domaine de la technologie biomédicale, et concerne en particulier un anticorps humanisé anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci et une utilisation associée. L'anticorps peut se lier de manière efficace et spécifique à PD-1, et peut bloquer de manière efficace la liaison de PD-1 à PD-L1 et PD-L2. Par conséquent, l'anticorps ou le fragment de liaison à l'antigène de celui-ci, et son acide nucléique, vecteur, cellule ou